WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Wednesday, May 31, 2017

FoxFeed Blog Getting Precise about Precision Medicine in Parkinson's

Posted by  Loren DeVito, PhD

Using the same medicine(s) to treat everyone with a given disease is the mainstay of modern medicine. Nonetheless, this "one-size-fits-all" approach doesn't always lead to outcomes patients want, as people often respond differently to the same medicine, and some may not respond at all. Researchers are working to address this challenge through "precision medicine."
Precision medicine involves tailoring therapies for individuals based on their genes, environment and/or lifestyle. You may be familiar with this approach for cancer -- unlike chemotherapy that kills cancer (and healthy) cells, successful personalized drugs instead target genetic mutations. But how might precision medicine be used to treat Parkinson's disease (PD)?
Parkinson's is a heterogeneous disorder, meaning no two individuals have the same symptoms, disease course or treatment response. If we could better understand what drives these differences, we could, in theory, develop better medicine.
As in cancer, some Parkinson's scientists believe genetic mutations may be the basis for tailored treatments. Even though known mutations account for fewer than 10 percent of total PD cases, a greater understanding of Parkinson's genetics already has led to critical discoveries believed to be applicable to all individuals with the disease. "Finding a common mechanism behind different suspected causes of Parkinson's suggests that there might also be a common means to treat or cure it," says Marco Baptista, PhD, director of research programs at The Michael J. Fox Foundation (MJFF). 
In 1997, a mutation in the alpha-synuclein gene was first linked to a family with Parkinson's. Though the mutation is extremely rare, alpha-synuclein protein clumps (Lewy bodies) are seen in the brains of nearly everyone with Parkinson's, and offer a potential target for slowing or stopping disease progression.
To date, five anti-alpha-synuclein therapies have advanced through drug development to arrive in clinical (human) testing. Other genetic mutations also are leading to treatments. LRRK2, although fairly uncommon, is the greatest known genetic contributor to PD and has inspired the development of LRRK2 inhibitor drugs expected to enter clinical trials within 18 months. Additionally, medications targeting GBA, the most common of the currently known PD genetic mutations, have made it into clinical testing. These are all examples of precision medicine.
"We will only get to true cures if we can move away from historical clinical disease definitions to one more nuanced and linked to underlying biology, genetics and pathology," said MJFF CEO Todd Sherer, PhD and co-authors in Personalized Medicine. "Truly transforming PD treatment into a precision approach will require tackling key research and regulatory challenges and the coordinated effort of the entire PD community."

Learn more about Parkinson's genetics at michaeljfox.org/pdgenetics
https://www.michaeljfox.org/foundation/news-detail.php?getting-precise-about-precision-medicine-in-parkinson

No comments:

Post a Comment